(Q28475076)

English

The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial

scientific article

In more languages

Statements

scholarly article

0 references

The effect of raltegravir intensification on low-level residual viremia in HIV-infected patients on antiretroviral therapy: a randomized controlled trial (English)

0 references

anti-retroviral agent

0 references

0 references

randomized controlled trial

1 reference

based on heuristic

inferred from title

1 reference

based on heuristic

inferred from title

object named as

Mary Kearney

14

0 references

David M. Margolis

object named as

David M Margolis

5

0 references

17

object named as

Joseph J Eron

0 references

15

object named as

John M Coffin

0 references

16

object named as

John W Mellors

0 references

8

object named as

Sarah Palmer

0 references

13

object named as

Ann Wiegand

0 references

author name string

Rajesh T Gandhi

1

0 references

Lu Zheng

2

0 references

Ronald J Bosch

3

0 references

Ellen S Chan

4

0 references

Sarah Read

6

0 references

Beatrice Kallungal

7

0 references

Kathy Medvik

9

0 references

Michael M Lederman

10

0 references

Nadia Alatrakchi

11

0 references

Jeffrey M Jacobson

12

0 references

language of work or name

0 references

publication date

10 August 2010

0 references

0 references

7

0 references

8

0 references

e1000321

0 references

copyright license

Creative Commons CC0 License

10 August 2010

1 reference

April 2022 Public Data File from Crossref

copyright status

copyrighted, dedicated to the public domain by copyright holder

0 references

Raltegravir with optimized background therapy for resistant HIV-1 infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2919424

19 March 2017

ART suppresses plasma HIV-1 RNA to a stable set point predicted by pretherapy viremia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2919424

19 March 2017

Short-course raltegravir intensification does not reduce persistent low-level viremia in patients with HIV-1 suppression during receipt of combination antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2919424

29 September 2017

Understanding HIV-1 latency provides clues for the eradication of long-term reservoirs

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2919424

29 September 2017

Treatment intensification does not reduce residual HIV-1 viremia in patients on highly active antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2919424

29 September 2017

Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2919424

29 September 2017

The challenge of finding a cure for HIV infection

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2919424

29 September 2017

Low-level viremia persists for at least 7 years in patients on suppressive antiretroviral therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2919424

29 September 2017

Limits on replenishment of the resting CD4+ T cell reservoir for HIV in patients on HAART

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2919424

29 September 2017

Genotypic analysis of HIV-1 drug resistance at the limit of detection: virus production without evolution in treated adults with undetectable HIV loads

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2919424

29 September 2017

New real-time reverse transcriptase-initiated PCR assay with single-copy sensitivity for human immunodeficiency virus type 1 RNA in plasma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2919424

29 September 2017

Productive infection maintains a dynamic steady state of residual viremia in human immunodeficiency virus type 1-infected persons treated with suppressive antiretroviral therapy for five years

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2919424

29 September 2017

T Cell Activation Is Associated with Lower CD4+T Cell Gains in Human Immunodeficiency Virus–Infected Patients with Sustained Viral Suppression during Antiretroviral Therapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2919424

29 September 2017

Interaction between endothelium and CD4+CD45RA+ lymphocytes. Role of the human CD38 molecule

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2919424

2 June 2018

Novel immunoregulatory functions of phenotypically distinct subpopulations of CD4+ cells in the human neonate

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2919424

2 June 2018

Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1000321

21 January 2018

HIV-1 replication and immune dynamics are affected by raltegravir intensification of HAART-suppressed subjects.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1000321

21 January 2018

Determinants of CD4+ T cell recovery during suppressive antiretroviral therapy: association of immune activation, T cell maturation markers, and cellular HIV-1 DNA.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1000321

21 January 2018

Effect of baseline- and treatment-related factors on immunologic recovery after initiation of antiretroviral therapy in HIV-1-positive subjects: results from ACTG 384.

1 reference

https://api.crossref.org/works/10.1371%2FJOURNAL.PMED.1000321

21 January 2018

Characterization of lymphocyte subpopulations in cord blood

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2919424

27 November 2018

Residual HIV-1 RNA in blood plasma of patients taking suppressive highly active antiretroviral therapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20711481

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1371/JOURNAL.PMED.1000321

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q28475076&oldid=1870128039"